Special Drug Use-Results Survey for IMBRUVICA Capsules 140 mg

Special Drug Use-Results Survey for IMBRUVICA Capsules 140 mg - Special Drug Use-Results Survey for IMBRUVICA Capsules 140 mg

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021963

Enrollment

200

Registered

2016-05-09

Start date

2016-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory chronic lymphocytic leukemia, including patients with small lymphocytic lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who administered IMBRUVICA

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness	—

Countries

Japan

Contacts

Public ContactFumi Nomura

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

fnomura@ITS.JNJ.com03-4411-8110

Outcome results